INTRODUCTION {#s1}
============

Schizophrenia (SCZ) is a severe and complex psychiatric disorder with a lifetime risk of approximately 1% among the population worldwide \[[@R1]\]. It is characterized by delusions, hallucinations, disorganization, dysfunction in normal affective responses, and altered cognitive functioning. Although the pathogenesis of SCZ remains unclear, the risk of SCZ is reportedly associated with complex environmental and genetic factors as well as their interaction with each other \[[@R2], [@R3]\]. Epidemiological studies indicate that the environmental risk factors for SCZ include urbanized area, minority group, cannabis use, developmental trauma, and pregnancy \[[@R4]\]. From family, twin and adoption studies, there is substantial evidence for the importance of the genetic components that influence the susceptibility to schizophrenia \[[@R1], [@R5]\]. The heritability of SCZ is estimated to be 64%-80% \[[@R6]\].

Recent association studies have shown that single nucleotide polymorphisms (SNPs) in *TCF7L2* (Transcription Factor 7-Like 2) affect the susceptibility to SCZ in both Arab and European populations \[[@R7], [@R8]\]. It also appears that chromosome 10q is remarkably rich in linkages to SCZ \[[@R9]\]. *TCF7L2* also known as *TCF4* locus on chromosome 10q25.2-25.3 and encodes a high mobility group box-containing transcription factor that plays a key role in the WNT signaling pathway \[[@R10]\]. This should not be confused with transcription factor 4 (*TCF4*), which share the *TCF4* symbol/alias in common with the *TCF7L2* locus. Previous reported that *TCF4* polymorphisms are associated with the risk of SCZ in the Han Chinese \[[@R11]\]. The WNT signaling pathway has been also associated with SCZ \[[@R12], [@R13]\]. *TCF7L2* is also thought to be a master regulator of glucose homeostasis through effects on proinsulin production and processing \[[@R14], [@R15]\]. Consistent with that idea, genetic variants of *TCF7L2* are associated with the risk of type 2 diabetes and gestational diabetes mellitus \[[@R16]--[@R20]\].

To further explore the relationship between *TCF7L2* polymorphisms and susceptibility to SCZ in a Chinese Han population, we designed a case-control study including 499 SCZ patients and 500 healthy controls to explore the potential associations between *TCF7L2* polymorphisms and SCZ risk in the Chinese Han population. Our results suggest the SNP rs12573128 in *TCF7L2* is associated with an increased risk of SCZ in the Chinese Han population.

RESULTS {#s2}
=======

The basic demographic characteristics of study participants are summarized in Table [1](#T1){ref-type="table"}. A total of 499 SCZ patients (263 males and 236 females) with a mean age of 36.7 (±13.3) and 500 healthy controls (192 males and 308 females) with a mean age of 50.4 (±7.8) were enrolled. Although the gender and age distributions differed between cases and controls (*P* \< 0.001), these two variables were adjusted in the subsequent multivariate unconditional logistic regression analysis to eliminate the residual confounding effects.

###### Characteristics of cases and controls

  Variable         Case(n=499)   Control(n=500)   *P*
  ---------------- ------------- ---------------- ----------
  Sex                                             \< 0.001
   Male            263 (52.7)    192 (38.4)       
   Female          236 (47.3)    308 (61.6)       
  Age                                             \< 0.001
  yr (mean ± SD)   36.7±13.3     50.4±7.8         

*P* \< 0.05 indicates statistical significance.

Six SNPs (rs12573128, rs7081062, rs7081062, rs7081062, rs6585205 and rs290489) in *TCF7L2* were successfully genotyped in both the cases and healthy controls. The sequences of the primers for each SNP polymerase chain reaction (PCR) and single base extension reaction are listed in Table [2](#T2){ref-type="table"}. The allele distributions and minor allele frequency (MAF) of the SNPs and results of Hardy-Weinberg equilibrium (HWE) test are shown in Table [3](#T3){ref-type="table"}. All six SNPs were in HWE in the control subjects (*P* \> 0.05). Comparison of differences in the frequency distributions of alleles between cases and controls using the Chi-squared test and found that allele "A" of rs12573128 was significantly associated with a 1.33-fold increase in risk of SCZ at a 5% level (OR = 1.33, 95% CI: 1.08-1.63, *P* = 0.006, Bonferroni adjusted *P* = 0.030). Comparisons of the SNP genotypes and risk of SCZ are listed in Table [4](#T4){ref-type="table"}. The AA genotype of rs12573128 was associated with significantly higher risk of SCZ than the GG genotype both before and after adjustment for age and gender (OR = 2.07, 95% CI: 1.49-5.92, *P* = 0.013; adjusted OR = 2.97, 95% CI: 1.49-5.92, *P* = 0.002, respectively).

###### Sequence of oligonucleotide primers used for the analysis of *TCF7L2* polymorphisms

  SNP-ID       1st-PCRP                          2nd-PCRP                          UEP
  ------------ --------------------------------- --------------------------------- ------------------------------
  rs12573128   ACGTTGGATGCAGGTAACT TGCTCAAGAGG   ACGTTGGATGCATTCTTCTG AGGTATGGAC   TGGACTTAAATTAGCT AATTAGG
  rs7081062    ACGTTGGATGCCTTTAAGT TCTCTTTCAAG   ACGTTGGATGTGAAGAAGCC AAGAGTTTCC   AGAGTTTCCTGTTAATT AAAAAGA
  rs4918789    ACGTTGGATGCAAAAGGCA AGGCGATTTTC   ACGTTGGATGCATGGTGTAC AACTCACACT   TTTGCTCTCTACA CCCTCA
  rs3750804    ACGTTGGATGAGAAAGGTG CCAGCTTCAAC   ACGTTGGATGTTTCTGGGGC GGTCGCAGG    aCGCAGGCTGACTAACA
  rs6585205    ACGTTGGATGTATTGACCC AACTTGGTCCC   ACGTTGGATGCTCTTGCCAT TCCTGGTTTC   actgGCCATTCCTGGTTTCA TCTAAGT
  rs290489     ACGTTGGATGTGCTGTCCC CAGCTTCTTTC   ACGTTGGATGCTTGACCTGT CTTTCCAGGC   TTCCAGGCCCTTCTC

Abbreviations: SNP: Single nucleotide polymorphism; PCRP: Polymerase chain reaction primer; UEP: Unique base extension primer.

Sequences are written in the 5′→3′ (left to right) orientation.

###### Allele frequencies in cases and controls and odds ratio estimates for SCZ

  SNP-ID       Band      Position    Role     Alleles A/B   MAF     HWE     OR      95% CI   *P*^a^   *P*^b^           
  ------------ --------- ----------- -------- ------------- ------- ------- ------- -------- -------- -------- ------- -------
  rs12573128   10q25.2   114730797   Intron   A/G           0.278   0.225   0.200   1.33     1.08     1.63     0.006   0.030
  rs7081062    10q25.2   114740745   Intron   G/A           0.252   0.224   0.798   1.17     0.95     1.43     0.142   0.710
  rs4918789    10q25.2   114821807   Intron   G/T           0.050   0.039   0.537   1.30     0.85     2.00     0.225   1.125
  rs3750804    10q25.2   114833850   Intron   T/C           0.231   0.241   0.541   0.95     0.77     1.17     0.616   3.080
  rs6585205    10q25.2   114859164   Intron   T/G           0.459   0.440   1.000   1.08     0.90     1.29     0.395   1.975
  rs290489     10q25.3   114907055   Intron   A/G           0.342   0.348   0.554   0.98     0.81     1.17     0.791   3.955

Abbreviations: SNP: Single nucleotide polymorphism; MAF: Minor allele frequency; HWE: Hardy-Weinberg equilibrium; OR: Odds ratio; 95% CI: 95% Confidence interval.

^a^*P* values were calculated using the Chi-Square test.

^b^*P* values were adjusted by Bonferroni correction.

*P* \< 0.05 indicates statistical significance.

###### Genotypes of the six SNPs and their associations with risk of SCZ

  SNP-ID       Genotype   Case(N)   Control(N)   Without adjustment   With adjustment                              
  ------------ ---------- --------- ------------ -------------------- ----------------- ------- ------ ----------- -------
  rs12573128   GG         257       295          1.00                 \-                        1.00   \-          
               AG         205       185          1.27                 0.98-1.65         0.070   1.34   0.98-1.83   0.067
               AA         36        20           2.07                 1.17-3.66         0.013   2.97   1.49-5.92   0.002
  rs7081062    AA         275       302          1.00                 \-                        1.00   \-          
               GA         195       172          1.25                 0.96-1.62         0.101   1.30   0.95-1.7    0.101
               GG         28        26           1.18                 0.68-2.07         0.556   1.38   0.70-2.73   0.358
  rs4918789    TT         448       462          1.00                 \-                        1.00   \-          
               GT         50        37           1.39                 0.89-2.17         0.143   1.43   0.86-2.39   0.169
               GG         0         1            0.00                 \-                0.999   0.00   \-          0.999
  rs3750804    CC         293       285          1.00                 \-                        1.00   \-          
               TC         181       189          0.93                 0.72-1.21         0.594   0.85   0.62-1.17   0.322
               TT         25        26           0.94                 0.53-1.66         0.819   1.08   0.55-2.12   0.815
  rs6585205    GG         142       156          1.00                 \-                        1.00   \-          
               TG         255       247          1.13                 0.85-1.51         0.390   1.02   0.72-1.44   0.903
               TT         101       96           1.16                 0.81-1.66         0.431   1.30   0.85-1.99   0.234
  rs290489     GG         222       209          1.00                 \-                        1.00   \-          
               AG         211       234          0.85                 0.65-1.11         0.226   0.85   0.62-1.16   0.302
               AA         65        57           1.07                 0.72-1.61         0.730   0.95   0.58-1.55   0.832

Abbreviations: SNP: Single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval.

*P* values were calculated using the Wald test.

*P* \< 0.05 indicates statistical significance.

The results of genetic model analyses (dominant, recessive and additive) using unconditional logistic regression analysis after adjustment with age and gender are summarized in Table [5](#T5){ref-type="table"}. We determined that SNP rs12573128 was associated with 1.47-fold, 2.64-fold and 1.50-fold increased risk of SCZ in the dominant, additive and recessive models, respectively (adjusted OR = 1.47, 95% CI = 1.09-1.99, *P* = 0.012; adjusted OR = 2.64, 95% CI = 1.34-5.18, *P* = 0.005 and adjusted OR = 1.50, 95% CI = 1.17-1.93, *P* = 0.002, respectively).

###### Genetic model analyses of the association between the SNPs and SCZ with adjustment for age and gender

  SNP-ID       Dominant   Recessive   Additive                                                             
  ------------ ---------- ----------- ---------- ------- ------ ------ ------ ------- ------ ------ ------ -------
  rs12573128   1.47       1.09        1.99       0.012   2.64   1.34   5.18   0.005   1.50   1.17   1.93   0.002
  rs7081062    1.31       0.97        1.77       0.080   1.24   0.64   2.44   0.524   1.24   0.97   1.60   0.090
  rs4918789    1.41       0.85        2.34       0.185   \-     \-     \-     0.999   1.38   0.84   2.26   0.209
  rs3750804    0.88       0.65        1.19       0.403   1.15   0.60   2.24   0.673   0.93   0.73   1.20   0.593
  rs6585205    1.09       0.79        1.51       0.588   1.28   0.88   1.85   0.192   1.13   0.91   1.39   0.271
  rs290489     0.87       0.64        1.17       0.347   1.03   0.64   1.65   0.902   0.93   0.74   1.16   0.521

Abbreviations: SNP: Single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval.

*P* \< 0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

The present study of 999 participants (499 SCZ patients and 500 healthy controls) was designed to investigate whether *TCF7L2* SNPs previously associated with the risk of type 2 diabetes and SCZ in an Arab population are associated with the risk of SCZ in a Chinese Han population. Our results indicated that the SNP rs12573128 in *TCF7L2* increases risk of SCZ.

*TCF7L2* is a reportedly transcription factor and a key component of the canonical WNT signaling pathway that regulates cell proliferation and differentiation \[[@R21], [@R22]\]. This pathway plays role in central nervous system (CNS) development \[[@R23]\], and is associated with SCZ \[[@R13]\]. It was previously observed that some *TCF7L2* polymorphisms were associated with an increased risk of SCZ in Arab and European populations \[[@R7], [@R8]\], though the molecular and cellular mechanisms through which *TCF7L2* act in this regard remain unclear. In the adult mouse, levels of *TCF7L2* expression are high in thalamus and tectum, with lower expression levels in the hypothalamus and other areas. This suggests *TCF7L2* may play a key role in mediating autonomic homeostasis \[[@R24]\]. Moreover, *TCF7L2* expression in the CNS is characterized by the presence of several splice variants, expression of which in mice differs among postmitotic neurons, immature neural precursors and intestinal epithelum \[[@R25]\]. Furthermore, a uniquely spliced *TCF7L2* form of may share neuroendocrine functions important for human brain, pancreatic islets and gut \[[@R26]\]. This is consistent with the finding that SCZ patients are at increased risk of comorbidities such as type 2 diabetes, and that TCF7L2 is associated with type 2 diabetes \[[@R7], [@R8]\]. We excluded patients with comorbidities from the study so that our results would not be affected by comorbidities.

The present study is generally consistent with the earlier finding that rs12573128 was associated with SCZ risk in an Arab population \[[@R8]\]. Our result suggests SNP rs12573128 affects WNT signaling to impact essential functions of *TCF7L2* during neural development, and may also impact the maturity of oligodendrocyte progenitor cells associated with the pathogenesis of SCZ.

This study has some potential limitations. First, the sample size is relatively small, and the participants included only a Chinese Han population. Second, although several confounders were adjusted for in the statistical analyses, we could not completely eliminate the potential influences of these factors on the results. Third, we conducted no functional analyses of the genetic variants in *TCF7L2*. In future studies with larger samples, functional characterizations will be important for validation of our findings.

In conclusion, our results indicate that SNP rs12573128 in *TCF7L2* was is associated with an increased risk of SCZ in a Chinese Han population, and could potentially serve as a clinically important pre-diagnostic marker.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

The study was approved by the Ethics Committee of the Psychiatric Hospital of Xi'an and Xizang Minzu University (Shaanxi, China), and complied with the Declaration of Helsinki. All participants gave written informed consent prior to participation in the study.

Study participants {#s4_2}
------------------

We recruited 499 SCZ patients form the Psychiatric Hospital of Xi'an, Shanxi province between April 2011 and January 2015, and the sample set is same as the former study on association between TCF4 polymorphisms and SCZ risk \[[@R11]\]. The patients were interviewed by at least two experienced senior psychiatrists and diagnosed strictly according to the criteria of the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) based on the Chinese version of the SCID-1 (Structured Clinical Interview for DSM-IV Axis I Disorders). In addition, 500 healthy controls were randomly selected from among unrelated volunteers recruited through advertisements in Xi'an city and its vicinity. These controls were screened using the SCID-I, non-patient edition. The inclusion and exclusion criteria were as follows. (1) All participants were genetically unrelated ethnic Han Chinese whose ancestors had lived in the region for at least three generations. (2) SCZ patients who had comorbidity, such as diabetes mellitus, hypertension or any endocrine disorder were excluded. (3) All the SCZ patients were recruited without age, sex, or disease stage restriction. (4) Healthy subjects were excluded if they had a family history of psychiatric disorder, or a history of hypothyroidism, uncontrolled hypertension or diabetes, or significant drug or alcohol abuse.

Clinical data and demographic information {#s4_3}
-----------------------------------------

The basic characteristics of all controls, including residential region, ethnicity, sex, age, family history and alcohol intake were collected by well-trained interviewers using a standardized questionnaire. Clinical information about the patients was collected from medical records and pathology reports.

DNA extraction {#s4_4}
--------------

We collected 5 mL of peripheral venous blood from each participant using vacutainer tubes containing ethylene diamine tetra-acetic acid (EDTA), which were then stored at −80°C. Genomic DNA was extracted from the blood samples using a GoldMag-Mini Whole Blood Genomic DNA Purification Kit according to the manufacturer\'s protocol (GoldMag. Co. Ltd., Xi'an, China). DNA concentration and purity were evaluated using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA, USA).

SNP selection and genotyping {#s4_5}
----------------------------

We selected six SNPs (rs12573128, rs7081062, rs7081062, rs7081062, rs6585205 and rs290489) reportedly associated with the risk of type 2 diabetes \[[@R16]--[@R19]\] and SCZ \[[@R8]\]. The MAFs of all of the SNPs were \>5% in the HapMap Han Chinese population. PCR and extension primers for the SNPs were designed using the Sequenom MassARRAY Assay Design 3.0 software (Sequenom, San Diego, CA, USA). Genotyping of the SNPs was performed with the Sequenom MassARRAY platform according to the standard instructions recommended by the manufacturer (Sequenom, San Diego, CA, USA) \[[@R27]\]. Sequenom Typer 4.0 software was used for data management and analysis.

Statistical analyses {#s4_6}
--------------------

The SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel (Microsoft Corp., Redmond, WA, USA) were used for statistical analyses. The gender distribution was compared using the Chi-squared test, while the age among between the cases and controls was assessed using Welch\'s t test. Genotypic frequencies in the controls were tested for departure from the HWE using Firsher\'s exact test. The allele frequencies of the cases and controls were calculated by use of Chi-squared test/Firsher\'s exact test, and we performed Bonferroni correction to adjust the *P* values. The genotype frequencies of the cases and controls were calculated by the Wald test. The relative risk was estimated based on odds ratios (ORs) and 95% confidence intervals (CIs) \[[@R28]\]. Genetic model analyses (dominant, recessive and additive) were applied using PLINK software to assess the significance of SNPs \[[@R29]\]. ORs and 95% CIs were calculated using unconditional logistic regression analysis with adjustment for age and gender. All *P*-values presented were two sided, and *P* value \< 0.05 was considered statistically significant.
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